The FDA on September 6, 2013 approved ABRAXANE® for use in combination with GEMZAR® (Gemcitabine) for the first line treatment of patients with metastatic adenocarcinoma of the pancreas. ABRAXANE® is an injectable suspension and is a product of Celgene Corporation.
Bottom Ad
Advertisement
Subscribe
